Lysine methylation in cancer: SMYD3-MAP3K2 teaches us new lessons in the Ras-ERK pathway

BioEssays

Volumn 36, Issue 12, 2014, Pages 1162-1169

  Colón Bolea, Paula ^a   Crespo, Piero ^a  

^a University of Cantabria   (Spain)

Author keywords

Cancer; ERK; Lysine methylation; Lysine methyltransferases; MAP3K2; Ras; SMYD3

Indexed keywords

LYSINE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATASE; RAS PROTEIN;

ARTICLE; CHROMATIN; ENZYME ACTIVATION; ENZYME BINDING; HUMAN; METHYLATION; NEOPLASM; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 85027930208     PISSN: 02659247     EISSN: 15211878     Source Type: Journal    
DOI: 10.1002/bies.201400120     Document Type: Article

References (90)

1. Black JC, Van Rechem C, Whetstine JR. 2012. Histone lysine methylation dynamics: establishment, regulation, and biological impact. Mol Cell 48: 491-507.
2. Lanouette S, Mongeon V, Figeys D, Couture JF. 2014. The functional diversity of protein lysine methylation. Mol Syst Biol 10: 724.
3. Zhang X, Wen H, Shi X. 2012. Lysine methylation: beyond histones. Acta Biochim Biophys Sin (Shanghai) 44: 14-27.
4. Tschiersch B, Hofmann A, Krauss V, Dorn R, et al. 1994. The protein encoded by the Drosophila position-effect variegation suppressor gene Su(var)3-9 combines domains of antagonistic regulators of homeotic gene complexes. EMBO J 13: 3822-31.
5. Feng Q, Wang H, Ng HH, Erdjument-Bromage H, et al. 2002. Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Curr Biol 12: 1052-8.
6. Dillon SC, Zhang X, Trievel RC, Cheng X. 2005. The SET-domain protein superfamily: protein lysine methyltransferases. Genome Biol 6: 227.
7. Chuikov S, Kurash JK, Wilson JR, Xiao B, et al. 2004. Regulation of p53 activity through lysine methylation. Nature 432: 353-60.
8. Takawa M, Cho HS, Hayami S, Toyokawa G, et al. 2012. Histone lysine methyltransferase SETD8 promotes carcinogenesis by deregulating PCNA expression. Cancer Res 72: 3217-27.
9. Yang J, Huang J, Dasgupta M, Sears N, et al. 2010. Reversible methylation of promoter-bound STAT3 by histone-modifying enzymes. Proc Natl Acad Sci USA 107: 21499-504.
10. Huq MD, Ha SG, Wei LN. 2008. Modulation of retinoic acid receptor alpha activity by lysine methylation in the DNA binding domain. J Proteome Res 7: 4538-45.
11. Kontaki H, Talianidis I. 2010. Lysine methylation regulates E2F1-induced cell death. Mol Cell 39: 152-60.
12. Subramanian K, Jia D, Kapoor-Vazirani P, Powell DR, et al. 2008. Regulation of estrogen receptor alpha by the SET7 lysine methyltransferase. Mol Cell 30: 336-47.
13. Lu T, Jackson MW, Wang B, Yang M, et al. 2010. Regulation of NF-kappaB by NSD1/FBXL11-dependent reversible lysine methylation of p65. Proc Natl Acad Sci USA 107: 46-51.
14. He A, Shen X, Ma Q, Cao J, et al. 2012. PRC2 directly methylates GATA4 and represses its transcriptional activity. Genes Dev 26: 37-42.
15. Xie Q, Hao Y, Tao L, Peng S, et al. 2012. Lysine methylation of FOXO3 regulates oxidative stress-induced neuronal cell death. EMBO Rep 13: 371-7.
16. Pless O, Kowenz-Leutz E, Knoblich M, Lausen J, et al. 2008. G9a-mediated lysine methylation alters the function of CCAAT/enhancer-binding protein-beta. J Biol Chem 283: 26357-63.
17. Saddic LA, West LE, Aslanian A, Yates JR III, et al. 2010. Methylation of the retinoblastoma tumor suppressor by SMYD2. J Biol Chem 285: 37733-40.
18. Rathert P, Dhayalan A, Murakami M, Zhang X, et al. 2008. Protein lysine methyltransferase G9a acts on non-histone targets. Nat Chem Biol 4: 344-6.
19. Esteve PO, Chin HG, Benner J, Feehery GR, et al. 2009. Regulation of DNMT1 stability through SET7-mediated lysine methylation in mammalian cells. Proc Natl Acad Sci USA 106: 5076-81.
20. Polevoda B, Sherman F. 2007. Methylation of proteins involved in translation. Mol Microbiol 65: 590-606.
21. Roberts DM, Rowe PM, Siegel FL, Lukas TJ, et al. 1986. Trimethyllysine and protein function. Effect of methylation and mutagenesis of lysine 115 of calmodulin on NAD kinase activation. J Biol Chem 261: 1491-4.
22. Vermillion KL, Lidberg KA, Gammill LS. 2014. Cytoplasmic protein methylation is essential for neural crest migration. J Cell Biol 204: 95-109.
23. Chen B, Piel WH, Gui L, Bruford E, et al. 2005. The HSP90 family of genes in the human genome: insights into their divergence and evolution. Genomics 86: 627-37.
24. Donlin LT, Andresen C, Just S, Rudensky E, et al. 2012. Smyd2 controls cytoplasmic lysine methylation of Hsp90 and myofilament organization. Genes Dev 26: 114-9.
25. Hamamoto R, Toyokawa G, Nakakido M, Ueda K, et al. 2014. SMYD2-dependent HSP90 methylation promotes cancer cell proliferation by regulating the chaperone complex formation. Cancer Lett 351: 126-33.
26. Jakobsson ME, Moen A, Bousset L, Egge-Jacobsen W, et al. 2013. Identification and characterization of a novel human methyltransferase modulating Hsp70 protein function through lysine methylation. J Biol Chem 288: 27752-63.
27. Cho HS, Shimazu T, Toyokawa G, Daigo Y, et al. 2012. Enhanced HSP70 lysine methylation promotes proliferation of cancer cells through activation of Aurora kinase B. Nat Commun 3: 1072.
28. Kunizaki M, Hamamoto R, Silva FP, Yamaguchi K, et al. 2007. The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3. Cancer Res 67: 10759-65.
29. Hartsough EJ, Meyer RD, Chitalia V, Jiang Y, et al. 2013. Lysine methylation promotes VEGFR-2 activation and angiogenesis. Sci Signal 6: ra104.
30. Guerrera IC, Keep NH, Godovac-Zimmermann J. 2007. Proteomics study reveals cross-talk between Rho guanidine nucleotide dissociation inhibitor 1 post-translational modifications in epidermal growth factor stimulated fibroblasts. J Proteome Res 6: 2623-30.
31. Levy D, Liu CL, Yang Z, Newman AM, et al. 2011. A proteomic approach for the identification of novel lysine methyltransferase substrates. Epigenet Chromatin 4: 19.
32. Grant JE, Hu J, Liu T, Jain MR, et al. 2007. Post-translational modifications in the rat lumbar spinal cord in experimental autoimmune encephalomyelitis. J Proteome Res 6: 2786-91.
33. Dhayalan A, Kudithipudi S, Rathert P, Jeltsch A. 2011. Specificity analysis-based identification of new methylation targets of the SET7/9 protein lysine methyltransferase. Chem Biol 18: 111-20.
34. Wu CC, MacCoss MJ, Howell KE, Yates JR III. 2003. A method for the comprehensive proteomic analysis of membrane proteins. Nat Biotechnol 21: 532-8.
35. Black JC, Whetstine JR. 2013. Tipping the lysine methylation balance in disease. Biopolymers 99: 127-35.
36. Henning SM, Swendseid ME, Coulson WF. 1997. Male rats fed methyl- and folate-deficient diets with or without niacin develop hepatic carcinomas associated with decreased tissue NAD concentrations and altered poly(ADP-ribose) polymerase activity. J Nutr 127: 30-6.
37. Hamamoto R, Silva FP, Tsuge M, Nishidate T, et al. 2006. Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci 97: 113-8.
38. Komatsu S, Imoto I, Tsuda H, Kozaki KI, et al. 2009. Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma. Carcinogenesis 30: 1139-46.
39. Kondo Y, Shen L, Suzuki S, Kurokawa T, et al. 2007. Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas. Hepatol Res 37: 974-83.
40. Chen MW, Hua KT, Kao HJ, Chi CC, et al. 2010. H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM. Cancer Res 70: 7830-40.
41. Huang J, Dorsey J, Chuikov S, Perez-Burgos L, et al. 2010. G9a and Glp methylate lysine 373 in the tumor suppressor p53. J Biol Chem 285: 9636-41.
42. McCabe MT, Graves AP, Ganji G, Diaz E, et al. 2012. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc Natl Acad Sci USA 109: 2989-94.
43. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, et al. 2002. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419: 624-9.
44. Kleer CG, Cao Q, Varambally S, Shen R, et al. 2003. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 100: 11606-11.
45. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, et al. 2010. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 42: 722-6.
46. Kuo AJ, Cheung P, Chen K, Zee BM, et al. 2011. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Mol Cell 44: 609-20.
47. Wang Y, Zhang H, Chen Y, Sun Y, et al. 2009. LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell 138: 660-72.
48. Agger K, Cloos PA, Rudkjaer L, Williams K, et al. 2009. The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A-ARF locus in response to oncogene- and stress-induced senescence. Genes Dev 23: 1171-6.
49. van Haaften G, Dalgliesh GL, Davies H, Chen L, et al. 2009. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet 41: 521-3.
50. Duns G, van den Berg E, van Duivenbode I, Osinga J, et al. 2010. Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma. Cancer Res 70: 4287-91.
51. Liu G, Bollig-Fischer A, Kreike B, van de Vijver MJ, et al. 2009. Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer. Oncogene 28: 4491-500.
52. Northcott PA, Nakahara Y, Wu X, Feuk L, et al. 2009. Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet 41: 465-72.
53. Sarris M, Nikolaou K, Talianidis I. 2014. Context-specific regulation of cancer epigenomes by histone and transcription factor methylation. Oncogene 33: 1207-17.
54. Chervona Y, Costa M. 2012. Histone modifications and cancer: biomarkers of prognosis? Am J Cancer Res 2: 589-97.
55. Albert M, Helin K. 2010. Histone methyltransferases in cancer. Semin Cell Dev Biol 21: 209-20.
56. West LE, Gozani O. 2011. Regulation of p53 function by lysine methylation. Epigenomics 3: 361-9.
57. Ivanov GS, Ivanova T, Kurash J, Ivanov A, et al. 2007. Methylation-acetylation interplay activates p53 in response to DNA damage. Mol Cell Biol 27: 6756-69.
58. Huang J, Perez-Burgos L, Placek BJ, Sengupta R, et al. 2006. Repression of p53 activity by Smyd2-mediated methylation. Nature 444: 629-32.
59. Zhong X, Chen X, Guan X, Zhang H, et al. 2014. Overexpressions of G9a and MCM7 in esophageal squamous cell carcinoma associated with poor prognosis. Histopathology, in press, doi: 10.1111/his.12456.
60. Shi X, Kachirskaia I, Yamaguchi H, West LE, et al. 2007. Modulation of p53 function by SET8-mediated methylation at lysine 382. Mol Cell 27: 636-46.
61. West LE, Roy S, Lachmi-Weiner K, Hayashi R, et al. 2010. The MBT repeats of L3MBTL1 link SET8-mediated p53 methylation at lysine 382 to target gene repression. J Biol Chem 285: 37725-32.
62. Munro S, Khaire N, Inche A, Carr S, et al. 2010. Lysine methylation regulates the pRb tumour suppressor protein. Oncogene 29: 2357-67.
63. Cho HS, Hayami S, Toyokawa G, Maejima K, et al. 2012. RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation. Neoplasia 14: 476-86.
64. Lee JS, Kim Y, Kim IS, Kim B, et al. 2010. Negative regulation of hypoxic responses via induced Reptin methylation. Mol Cell 39: 71-85.
65. Wang GG, Cai L, Pasillas MP, Kamps MP. 2007. NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nat Cell Biol 9: 804-12.
66. Hamamoto R, Furukawa Y, Morita M, Iimura Y, et al. 2004. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol 6: 731-40.
67. Cock-Rada AM, Medjkane S, Janski N, Yousfi N, et al. 2012. SMYD3 promotes cancer invasion by epigenetic upregulation of the metalloproteinase MMP-9. Cancer Res 72: 810-20.
68. Van Aller GS, Reynoird N, Barbash O, Huddleston M, et al. 2012. Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation. Epigenetics 7: 340-3.
69. Liu C, Wang C, Wang K, Liu L, et al. 2013. SMYD3 as an oncogenic driver in prostate cancer by stimulation of androgen receptor transcription. J Natl Cancer Inst 105: 1719-28.
70. Zou JN, Wang SZ, Yang JS, Luo XG, et al. 2009. Knockdown of SMYD3 by RNA interference down-regulates c-Met expression and inhibits cells migration and invasion induced by HGF. Cancer Lett 280: 78-85.
71. Liu C, Fang X, Ge Z, Jalink M, et al. 2007. The telomerase reverse transcriptase (hTERT) gene is a direct target of the histone methyltransferase SMYD3. Cancer Res 67: 2626-31.
72. Calvo F, Agudo-Ibanez L, Crespo P. 2010. The Ras-ERK pathway: understanding site-specific signaling provides hope of new anti-tumor therapies. BioEssays 32: 412-21.
73. Matallanas D, Crespo P. 2010. New druggable targets in the Ras pathway? Curr Opin Mol Ther 12: 674-83.
74. Gaedcke J, Grade M, Jung K, Camps J, et al. 2010. Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas. Genes Chromosomes Cancer 49: 1024-34.
75. Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, et al. 2011. Differential gene expression signatures between colorectal cancers with and without KRAS mutations: crosstalk between the KRAS pathway and other signalling pathways. Eur J Cancer 47: 1946-54.
76. Mazur PK, Reynoird N, Khatri P, Jansen PW, et al. 2014. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer. Nature 510: 283-7.
77. Uhlik MT, Abell AN, Cuevas BD, Nakamura K, et al. 2004. Wiring diagrams of MAPK regulation by MEKK1, 2, and 3. Biochem Cell Biol 82: 658-63.
78. Cuevas BD, Abell AN, Johnson GL. 2007. Role of mitogen-activated protein kinase kinase kinases in signal integration. Oncogene 26: 3159-71.
79. Choi MC, Cohen TJ, Barrientos T, Wang B, et al. 2012. A direct HDAC4-MAP kinase crosstalk activates muscle atrophy program. Mol Cell 47: 122-32.
80. Eichhorn PJ, Creyghton MP, Bernards R. 2009. Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta 1795: 1-15.
81. Maruyama T, Kadowaki H, Okamoto N, Nagai A, et al. 2010. CHIP-dependent termination of MEKK2 regulates temporal ERK activation required for proper hyperosmotic response. EMBO J 29: 2501-14.
82. Fanger GR, Johnson NL, Johnson GL. 1997. MEK kinases are regulated by EGF and selectively interact with Rac/Cdc42. EMBO J 16: 4961-72.
83. Schmidt C, Peng B, Li Z, Sclabas GM, et al. 2003. Mechanisms of proinflammatory cytokine-induced biphasic NF-kappaB activation. Mol Cell 12: 1287-300.
84. Jura N, Scotto-Lavino E, Sobczyk A, Bar-Sagi D. 2006. Differential modification of Ras proteins by ubiquitination. Mol Cell 21: 679-87.
85. Kubota Y, O'Grady P, Saito H, Takekawa M. 2011. Oncogenic Ras abrogates MEK SUMOylation that suppresses the ERK pathway and cell transformation. Nat Cell Biol 13: 282-91.
86. Yang MH, Nickerson S, Kim ET, Liot C, et al. 2012. Regulation of RAS oncogenicity by acetylation. Proc Natl Acad Sci USA 109: 10843-8.
87. Yeung F, Ramsey CS, Popko-Scibor AE, Allison DF, et al. 2014. Regulation of the mitogen-activated protein kinase kinase (MEK)-1 by NAD-dependent deacetylases. Oncogene, in press, doi: 10.1038/onc.2014.39.
88. Shanley TP, Vasi N, Denenberg A, Wong HR. 2001. The serine/threonine phosphatase, PP2A: endogenous regulator of inflammatory cell signaling. J Immunol 166: 966-72.
89. Prickett TD, Brautigan DL. 2007. Cytokine activation of p38 mitogen-activated protein kinase and apoptosis is opposed by alpha-4 targeting of protein phosphatase 2A for site-specific dephosphorylation of MEK3. Mol Cell Biol 27: 4217-27.
90. Helin K, Dhanak D. 2013. Chromatin proteins and modifications as drug targets. Nature 502: 480-8.